Dysregulation of SOCE and/or mutations of CASQ1 have been reported in human patients or animal models with skeletal muscle diseases such as tubular aggregate myopathy (TAM) or malignant hyperthermia [23,27,28,29,30]. This evidence concerns the gene CASQ1 and transient myeloproliferative syndrome.